Literature DB >> 14707798

Estimation of annual HIV transmission rates in the United States, 1978-2000.

David R Holtgrave1.   

Abstract

The HIV/AIDS epidemic in the United States generally has been characterized by AIDS case incidence and AIDS-associated death rates; in a more limited fashion, the epidemic has also been described by AIDS prevalence; population-specific HIV prevalence; and HIV incidence statistics. However, HIV transmission rate information (i.e., the rate of transmission from persons living with HIV to HIV-seronegative persons) has received relatively little attention. The purpose of the present paper is to estimate the annual HIV transmission rate (from HIV-seropositive to HIV-seronegative persons) in the United States for the time period 1978-2000 and to discuss the practical utility of the findings. Using as input annual AIDS-associated deaths and HIV incidence (both variables, especially the latter, contain some element of uncertainty), the model described here finds that HIV transmission rates have dropped dramatically in the United States since the beginning of the epidemic and stayed approximately between 4.00-4.34% during the 1990s. This implies a programmatic success in that for more than roughly 95% of persons living with HIV in any given year, no HIV transmission occurs. Research is urgently needed to fully understand the circumstances that allow the remaining instances of HIV transmission to take place; moreover, serostatus-appropriate HIV-related services are needed to disrupt these remaining instances of transmission.

Entities:  

Mesh:

Year:  2004        PMID: 14707798     DOI: 10.1097/00126334-200401010-00013

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  10 in total

1.  How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?

Authors:  Steven D Pinkerton
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

2.  Infections prevented by increasing HIV serostatus awareness in the United States, 2001 to 2004.

Authors:  Steven David Pinkerton; David Robert Holtgrave; Carol Lynne Galletly
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

3.  HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002.

Authors:  Barbara Tempalski; Spencer Lieb; Charles M Cleland; Hannah Cooper; Joanne E Brady; Samuel R Friedman
Journal:  J Urban Health       Date:  2008-11-18       Impact factor: 3.671

Review 4.  HIV transmission rate modeling: a primer, review, and extension.

Authors:  Steven D Pinkerton
Journal:  AIDS Behav       Date:  2012-05

5.  A population-based study of HIV testing practices and perceptions in 4 U.S. states.

Authors:  Traci A Takahashi; Kay M Johnson; Katharine A Bradley
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

6.  Can increasing awareness of HIV seropositivity reduce infections by 50% in the United States?

Authors:  David R Holtgrave; Steven D Pinkerton
Journal:  J Acquir Immune Defic Syndr       Date:  2007-03-01       Impact factor: 3.731

7.  HIV Transmission Rates in the United States, 2006-2008.

Authors:  David R Holtgrave; H Irene Hall; Joseph Prejean
Journal:  Open AIDS J       Date:  2012-03-30

8.  Diversity in HIV epidemic transitions in India: An application of HIV epidemiological metrices and benchmarks.

Authors:  Pradeep Kumar; Chinmoyee Das; Arvind Kumar; Damodar Sahu; Sanjay K Rai; Sheela Godbole; Elangovan Arumugam; Lakshmi P V M; Shanta Dutta; H Sanayaima Devi; Vishnu Vardhana Rao Mendu; Shashi Kant; Arvind Pandey; Dandu Chandra Sekhar Reddy; Sanjay Mehendale; Shobini Rajan
Journal:  PLoS One       Date:  2022-07-18       Impact factor: 3.752

9.  Clinical and Economic Effects of a Pharmacist-Administered Antiretroviral Therapy Adherence Clinic for Patients Living with HIV.

Authors:  Thomas J Dilworth; Pamela W Klein; Renée-Claude Mercier; Matthew E Borrego; Bernadette Jakeman; Steven D Pinkerton
Journal:  J Manag Care Spec Pharm       Date:  2018-02

10.  Costs and consequences of the US Centers for Disease Control and Prevention's recommendations for opt-out HIV testing.

Authors:  David R Holtgrave
Journal:  PLoS Med       Date:  2007-06       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.